Table 1

Subtype specificity of RB1 LOH and RB1 and p16INK4a immunohistochemistry

Basal-like
 HER2-enriched
 Luminal A
 Luminal B
 Normal-like
 Total
RB1 LOH






LOH positive
 13 (48.2)
 3 (11.1)
 3 (11.1)
 8 (29.6)
 0 (0)
 27
LOH negative
 5 (12.5)
 6 (15.0)
 17 (42.5)
 5 (12.5)
 7 (17.5)
 40
Total
 18
 9
 20
 13
 7
 67
 p = 2.26E-04








RB IHC






0
 6 (42.9)
 2 (14.3)
 3 (21.4)
 3 (21.4)
 0 (0)
 14
1+
 13 (29.6)
 5 (11.4)
 14 (31.8)
 4 (9.1)
 8 (18.2)
 44
2+
 5 (12.8)
 6 (15.4)
 14 (35.9)
 6 (15.4)
 8 (20.5)
 39
3+
 7 (35.0)
 2 (10.0)
 4 (20.0)
 7 (35.0)
 0 (0)
 20
Total
 31
 15
 35
 20
 16
 117
 p = 0.0644








p16 IHC






0
 2 (8.0)
 4 (16.0)
 8 (32.0)
 6 (24.0)
 5 (20.0)
 25
1+
 5 (15.2)
 3 (9.1)
 15 (45.5)
 5 (15.2)
 5 (15.2)
 33
2+
 4 (13.8)
 4 (13.8)
 9 (31.0)
 6 (20.7)
 6 (20.7)
 29
3+
 22 (68.8)
 4 (12.5)
 3 (9.4)
 3 (9.4)
 0 (0)
 32
Total
 33
 15
 35
 20
 16
 119
 p = 1.41E-05

0 = negative, 1+ = weak positive, 2+ = moderate positive, 3+ = strong positive. P-values determined by Fisher's exact test.

HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; LOH = loss of heterozygosity; RB1 = retinoblastoma.

Herschkowitz et al. Breast Cancer Research 2008 10:R75   doi:10.1186/bcr2142

Open Data